ArticleBMJ open2021

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.

Daisuke Yabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.